Among the Oji-Cree of northern Ontario, women have both a higher prevalence and an earlier onset of type 2 diabetes compared to men. We studied the relationship between HNF1A S319 and both the presence of and the age-of-onset of type 2 diabetes in women and men separately. We found that: 1) in women, there was a signi®cant difference in the mean age-of-onset of type 2 diabetes according to HNF1A genotype; and 2) in men, there was no difference in the mean age-of-onset of type 2 diabetes according to HNF1A genotype. The ®ndings indicate that HNF1A S319 is associated with increased susceptibility to type 2 diabetes in both men and women, but with earlier age-of-onset in women only. One factor that might account for the gender difference in the onset of HNF1A S319-associated type 2 diabetes is the greater prevalence and severity, and earlier onset of, obesity among female Oji-Cree.
Introduction
The prevalence of type 2 diabetes mellitus in Canadian Oji-Cree is among the highest in the world. 1 We previously showed that the Oji-Cree have a private variant in the HNF1A gene, namely G319S, which is strongly associated with type 2 diabetes. 2 HNF1A G319S creates a susceptibility state, which results in clinical expression of type 2 diabetes in the presence of a high-fat diet and sedentary lifestyle. 2 Furthermore, HNF1A S319 has a gene ± dosage in¯uence on the age-of-onset of diabetes in the overall Oji-Cree sample, with each copy of the variant allele being associated with a 10 y advance in the age-of-onset of type 2 diabetes. 2 Oji-Cree women have a higher prevalence and younger age of expression of type 2 diabetes than Oji-Cree men. 1 One factor underlying these gender differences may be the greater burden of obesity amongst the women. 1 We set out to determine why the typical type 2 diabetes related to HNF1A S319 is expressed at younger ages in Oji-Cree women compared with men. 1 
Methods
The baseline clinical attributes of this cohort have been reported previously. 1 ± 5 Type 2 diabetes and normal glucose tolerance (non-diabetic) were diagnosed using established criteria. 1 Fasting plasma concentrations of glucose and post-challenge glucose were determined as described. 1 ± 5 Restriction analysis using BseDI detected the DNA change underlying the HNF1A G319S variation. 2 SAS (Version 6.12) was used for statistical comparisons. 6 Between-group differences in allele and genotype frequencies were compared using w 2 analysis and a two-tail Fisher's exact test, respectively. Estimates of relative risk of type 2 diabetes between genotypes were determined using odds ratios (OR) from the Mantel ± Haenszel method. The LIFETEST Wilcoxon procedure was used to determine betweengenotype differences in the age-of-onset of type 2 diabetes. Analysis of variance (ANOVA) with the general linear models procedure in SAS was used to determine the sources of variation for log BMI, log fasting glucose, log fasting insulin, log fasting Cpeptide, log fasting leptin and log plasma glucose 2 h after a 75 g glucose load. F-tests were computed from the type III sums of squares. 6 Independent variables for each ANOVA were sex, age and HNF1A genotype, with body mass index (BMI) included for biochemical traits.
Results
We studied 118 adults with type 2 diabetes, of whom 47 were men, and 335 adults with normal glucose tolerance, of whom 164 were men. Baseline attributes of the study sample were the same as previously reported. 2 In women, the HNF1A S319 allele frequency was 0.176 (25a142) in those with diabetes and 0.067 (23a342) in those without diabetes (w 2 13.5, P`0.0001). In men, the HNF1A S319 allele frequency was 0.266 (25a94) in those with diabetes and 0.110 (36a328) in those without diabetes (w 2 14.5, P`0.0001). The allele frequencies were similar to those previously reported for the overall sample. 2 Genotype frequencies did not deviate from those predicted by the Hardy ± Weinberg equation. In the overall sample, the genotype frequencies of subjects with HNF1A G319aG319, S319aG319 and S319a S319 were 0.619 (73a118), 0.338 (40a118) and 0.0429 (5a118) in subjects with type 2 diabetes, and 0.827 (277a335), 0.170 (57a335) and 0.003 (1a335) in subjects without type 2 diabetes (w 2 27, P`0.0001).
In women, the OR for type 2 diabetes for a S319aG319 heterozygote compared with a G319aG319 homozygote was 2.0 (95% con®dence Figure 1 (A) Cumulative age-of-onset curves for female OjiCree with type 2 diabetes according to HNF1A genotype. The curves for the HNF1A S319aG319 heterozygotes the G319aG319 homozygotes were signi®cantly different (P 0.010). The curves for the HNF1A S319aS319 homozygotes and G319aG319 homozygotes were also signi®cantly different (P 0.0002). (B) Cumulative age-of-onset curves for male Oji-Cree with type 2 diabetes according to HNF1A genotype. The curves for the HNF1A S319aG319 heterozygotes and G319aG319 homozygotes were not signi®cantly different (P 0.73). The curves for the HNF1A S319aS319 homozygotes and G319aG319 homozygotes were also not signi®cantly different (P 0.79). HNF1A G319S, gender and diabetes RA Hegele et al intervals (CI) 1.3 ± 3.0). The OR for type 2 diabetes for a S319aS319 homozygote compared with a G319aG319 homozygote was 4.1 (95% CI 1.3 ± 12.6). In men, the OR for type 2 diabetes for a S319aG319 heterozygote compared with a G319aG319 homozygote was 2.2 (95% CI 1.3 ± 3.7). The OR for type 2 diabetes for a S319aS319 homozygote compared with a G319aG319 homozygote was 4.6 (95% CI 1.72 ± 12.4). Figure 1A shows the cumulative proportion of women with type 2 diabetes by age-of-onset, according to HNF1A genotype. the curves for the S319aG319 heterozygotes and G39aG319 homozygotes were signi®cantly different (Wilcoxon P 0.010). The curves of for the S319aS319 homozygotes and G319aG319 homozygotes were also signifcantly different (Wilcoxon P 0.0002). Figure 1B shows the cumulative proportion of men with type 2 diabetes by age-of-onset. The curves for the three HNF1A genotype classes in men were not signi®-cantly different.
Women and men with and without diabetes were evaluated separately for differences between genotypes in plasma biochemical traits, and no signi®cant between-genotype difference was seen for any biochemical trait (data not shown).
Discussion
The increased risk of type 2 diabetes in HNF1A S319aG319 heterozygotes and S319aS319 homozygotes compared with G319aG319 homozygotes was the same in both men and women. however, HNF1A S319 was associated with onset of type 2 diabetes at a signi®cantly younger age only in Oji-Cree women. The onset of diabetes in women with HNF1A S319aS319, S319aG319 and G319aG319 genotypes was in their third, fourth and ®fth decades of life, respectively. In contrast, Oji-Cree men had onset of their diabetes in the ®fth decade of life, irrespective of the HNF1A genotype.
A previous cross-sectional analysis indicated that more Oji-Cree women were obese for any particular age range than men (41.2% vs 27.2%, P`0.0001). 1 In order to formally demonstrate that women in Sandy Lake reached obesity milestones at a younger age than men, we performed a post hoc analysis using LIFE-TEST. 6 We determined the cumulative proportion of men and women with BMI 27 and 30 kgam 2 according to age in the overall Sandy Lake community (Figure 2 ). Between the ages of 10 and 25, Oji-Cree women attained a BMI of 27 kgam 2 at a signi®cantly faster rate than men (P 0.033), but there was no difference above the age of 25 y (Figure 2A ). Between the ages of 30 and 50, OjiCree women attained a BMI of 30 kgam 2 at a signi®cantly faster rate than men (P 0.041), but there was no difference above age 50 ( Figure 2B ). Thus, Oji-Cree women reached BMI cut-off points in signi®cantly greater proportions at younger ages than men. However, these differences were lost at older ages, presumably because the proportions eventually became the same in both sexes. Thus, HNF1A is strongly associated with diabetes in both genders, but it is associated with accelerated age-of-onset only in women. This appears to be related to the tendency of Oji-Cree women to develop obesity at younger ages than men. The issue could be resolved by future cellular, physiological andaor prospective clinical studies of the natural history and response to intervention of HNF1A S319-associated diabetes in the Oji-Cree.
